)

Catalyst Pharmaceuticals (CPRX) investor relations material
Catalyst Pharmaceuticals Baird Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Business model and strategic approach
Focuses on acquiring de-risked assets in orphan and rare diseases, leveraging partnerships with companies lacking commercialization infrastructure.
Operates with a lean internal structure, supported by specialty pharmacy, patient hub, and 3PL services.
Prioritizes immediately or nearly immediately accretive assets, with a strong emphasis on differentiated products and cultural fit in partnerships.
Maintains a strong balance sheet with $652 million in cash and no debt, enabling flexibility for future acquisitions.
Targets opportunities with peak sales up to $500 million, focusing on markets unattractive to larger players.
FIRDAPSE: Market dynamics and growth strategy
FIRDAPSE addresses Lambert-Eaton Myasthenic Syndrome (LEMS), split evenly between idiopathic and cancer-associated cases, with about 3,600 U.S. patients.
Business has grown 15% quarter over quarter, driven by expansion into oncology and improved testing and guideline updates.
Recent NCCN guideline inclusion and frictionless testing are expected to drive significant growth, especially in oncology practices.
Oncology market penetration is currently under 10%, with a long-term goal to exceed 50% diagnosis and treatment rates.
Full-year 2025 guidance is $355–$360 million in sales, with a $1.2 billion market potential.
AGAMREE: Launch progress and future plans
AGAMREE is positioned as a safer corticosteroid for Duchenne Muscular Dystrophy (DMD), with better bone health, stature, and reduced behavioral side effects.
Outreach to 100+ centers of excellence has resulted in broad adoption, with a focus now on deepening engagement and data dissemination.
The Summit Study, enrolling over five years, aims to generate long-term safety data to support label updates.
Early feedback highlights rapid behavioral improvements, benefiting patients and families.
2025 sales guidance is $100–$110 million, with a $1 billion market opportunity as steroid use expands from 70% to 95% of DMD patients.
Next Catalyst Pharmaceuticals earnings date

Next Catalyst Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage